Epitalon (epithalon) peptide
Also known as Epithalon, Epithalone, AEDG peptide, Ala-Glu-Asp-Gly
Epitalon (epithalon) is a four-amino-acid peptide modeled on a pineal-gland extract and marketed for telomeres and longevity. Nearly all of the evidence comes from one Russian research group, and no independent human trial exists.
Evidence grade D · 9 citations · Last reviewed October 2026
- Regulatory status
- Not FDA-approved. In a draft, non-binding policy released October 28, 2026, HHS says it does not intend to bring enforcement action against 503A compounding of epitalon acetate injected (subcutaneous or intramuscular) in intermittent courses when ten stated conditions are met. That is not approval.
- Common routes
- Subcutaneous · intramuscular injection, intermittent courses (the HHS policy's limits)
Epitalon: the quick answer
- What is Epitalon?
- A synthetic four-amino-acid peptide (Ala-Glu-Asp-Gly) modeled on epithalamin, a bovine pineal-gland extract, and sold for longevity.
- How strong is the evidence?
- One cell study behind the telomere claim and small human reports, mostly from one Russian group. The largest human studies used the pineal extract, not synthetic epitalon.
- US status (as of October 2026)
- Not FDA-approved. Under a draft, non-binding policy, HHS says it does not intend to bring enforcement action against 503A compounding of epitalon acetate when ten conditions are met, for subcutaneous or intramuscular injection given in intermittent courses only. Research-chemical vials are outside the policy.
Overview
Epitalon (also spelled epithalon or epithalone) is a four-amino-acid synthetic peptide usually abbreviated AEDG, for alanine, glutamic acid, aspartic acid and glycine. It was designed in Russia as a synthetic stand-in for epithalamin, an extract of the bovine pineal gland [6]. It is marketed for longevity, with claims that it switches on telomerase and lengthens telomeres.
Those claims rest on a small literature that comes almost entirely from Vladimir Khavinson's group in St. Petersburg. The telomerase finding is a single 2003 cell-culture study [2]. The human mortality reports used the pineal extract, not synthetic epitalon [4] [5]. An independent 2025 review calls the compound bioactive and promising while saying its mechanisms remain uncertain [6]. In a draft enforcement policy dated October 28, 2026, HHS says it does not intend to bring enforcement action against 503A pharmacies and physicians that compound epitalon, provided they meet ten conditions and supply it only as injections given in intermittent courses [1]. That changes how it can be obtained in the US, not what is known about it.
Regulatory status
No FDA approval exists for epitalon, for any indication. The October 28, 2026 HHS announcement is a draft and interim enforcement-discretion policy; it is not final, it binds neither HHS nor the public, and the comment period runs until November 13, 2026. Its premise is simple. FDA has not yet decided, through rulemaking, whether epitalon goes on the 503A bulk drug substances list, and until it does, HHS says it does not intend to bring enforcement action against a licensed physician, a Federal facility, or a State-licensed pharmacy compounding epitalon acetate as long as all ten conditions hold [1]. HHS adds a reminder that compounded drugs are unapproved and that FDA does not vet them for safety, effectiveness, or quality.
Route limits: the policy covers epitalon acetate in subcutaneous or intramuscular injectable forms dispensed in intermittent courses [1]. Continuous use, oral products, and nasal products fall outside it. The policy does not define a course length or a dose.
Beyond the route, the conditions call for a prescription for a named patient and epitalon as the product's only active ingredient, so blends are out. The bulk peptide is to come from an FDA-registered manufacturer, with a certificate of analysis that confirms identity, purity and potency and checks endotoxin, heavy metals, microbial limits and impurities. Packaging may include a 510(k)-cleared syringe and no other device, and one condition is that the label carries the sentence "This is a compounded drug product. Not for resale." Finally, any serious adverse event or quality defect goes to the states and to FDA MedWatch [1].
History: FDA placed epitalon in Category 2 on September 29, 2023, and it stayed there until April 22, 2026. The Pharmacy Compounding Advisory Committee voted to list it; CDER had advised the opposite [1]. HHS explained its decision in three parts. Newer certificates of analysis addressed CDER's quality questions, compounding use was documented, and in HHS's view CDER's safety worries came from mechanism rather than harm anyone had observed. HHS also pointed out that no side effects were reported in what little controlled human exposure exists, and that the documented regimens are intermittent [1]. An independent analysis of the advisory committee review appears in the compounding literature [8].
Where to get Epitalon
Every telehealth provider we track that offers Epitalon. Partners we work with are shown first.
Pepti
Best for: a low all-in starter price on compounded GLP-1s, with every dose price published up front
Editorial score · methodology
Editorial score · methodology
HuHealth
Best for: choosing your compounding pharmacy, or brand Zepbound and Wegovy at the maker's price plus a $59 care plan
Editorial score · methodology
Enhanced
Best for: prepaying for low-cost compounded GLP-1s with peptides available from one brand
Editorial score · methodology
Editorial score · methodology
RxPepsDirect
Best for: Lowest per-vial GLP-1 cost: sema $25, tirz $45, $39 telehealth Rx, 28 states
Editorial score · methodology
FormBlends
Best for: transparent, flat-priced compounded semaglutide or tirzepatide with no membership fee
Editorial score · methodology
ElitePhysiqMD
Best for: GLP-1 shoppers who want injectable or sublingual options with dose-by-dose pricing
Editorial score · methodology
Scripts Rx Direct
Best for: compounded peptides priced up front, including KPV, MOTS-c, epitalon and semax nasal spray
Editorial score · methodology
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
What does Epitalon do? Claims vs evidence
Each row is a claim as it is commonly marketed, the strongest kind of evidence behind it, and what that evidence found. Numbers in brackets point to the sources at the end of this page.
| Claim | Evidence | What the studies found | Sources |
|---|---|---|---|
| Lengthens telomeres | Cell studies only | One 2003 study in cultured human fetal fibroblasts found epitalon switched on telomerase and lengthened telomeres. It came from the group that developed epitalon and has not been shown in people. | Sources:[2] |
| Extends lifespan and lowers mortality | No direct evidence | No study of synthetic epitalon has measured lifespan or mortality in people. The Russian mortality reports (266 older adults; 79 coronary patients) used epithalamin, the pineal extract, and come from one research network. | Sources:[4][5] |
| Improves eyesight in retinitis pigmentosa | Human studies | A 2002 report from the developing group described better retinal function in rats and a positive clinical effect in 90% of treated patients. The abstract gives no patient count and no control group. | Sources:[3] |
| Regulates melatonin and sleep | Animal studies | An independent 2025 review lists effects on melatonin synthesis from cell, animal and computer-modeling studies and says the mechanisms remain uncertain. None of this is a human sleep study. | Sources:[6] |
Evidence levels, strongest first: FDA-approved use, human studies (of any size or design), animal studies, cell studies only, and no direct evidence (nothing tests the claim for this compound).
How it works
The central claim is about telomeres, the protective caps on chromosomes that shorten as cells divide. In a 2003 study, adding epitalon to cultured human fetal fibroblasts that normally lack telomerase induced expression of the enzyme's catalytic subunit, telomerase activity, and telomere elongation [2]. That is one cell-culture experiment from the originating group, and it has not built into an independent replication literature since.
The 2025 independent review lists other reported effects from cell, animal and computer-modeling work: influence on melatonin synthesis, changes in interleukin-2 mRNA, and effects on several enzymes including telomerase. Its authors write that it remains uncertain whether these are the sole mechanisms of action, and that physico-chemical and structural studies of the peptide are still limited [6]. A caution that applies to any telomerase claim: switching the enzyme on broadly is not automatically good, because telomerase reactivation is also a feature of many cancers.
What the evidence says
Synthetic epitalon in people: the main published human report is a 2002 paper on retinitis pigmentosa, an inherited retinal disease. It describes epitalon improving retinal function in Campbell rats and reports a positive clinical effect in 90% of treated patients with degenerative retinal lesions [3]. The abstract does not give the number of patients or describe a control group.
The pineal extract in people: a 2003 report followed 266 older adults for 6 to 8 years after courses of the thymus extract thymalin, the pineal extract epithalamin, or both, given during the first 2 to 3 years. Compared with controls, mortality was reported as 1.6 to 1.8 times lower among those given epithalamin, and 2.5 times lower with thymalin plus epithalamin [4]. A 2011 randomized study gave 39 older coronary patients six courses of epithalamin over three years alongside standard treatment, compared with 40 on standard treatment alone, and reported slower cardiovascular aging and significantly lower mortality over 15 years of follow-up [5]. Both studies come from the same research network, both used the extract rather than synthetic epitalon, and neither has been repeated by an independent group.
Evidence grade: D. The positive data are concentrated in one group, published largely in Russian and specialty journals, and the strongest human numbers belong to a different product. No independent randomized trial of synthetic epitalon for aging, lifespan, or any other outcome exists in PubMed, and no study reports weight loss.
Typical dosing
There is no established human dose of synthetic epitalon. The abstracts above report courses of treatment but do not state a dose for the synthetic peptide, and the extract studies used a different product. The HHS policy limits compounded epitalon to injection in intermittent courses but does not specify a dose or a course length [1]. We do not publish a protocol. If a clinician prescribes compounded epitalon, the dose and the length and spacing of courses are their decision, not a validated regimen.
Safety & side effects
Long-term human safety is unknown. HHS's justification notes that no side effects turned up in the few controlled human exposures on record [1], but those exposures are small in number and comes largely from the originating group. Absence of reported side effects in a few small studies is not the same as an established safety record, and the telomerase claim adds a specific question, because telomerase activity is a hallmark of many cancers.
Quality is a documented problem in the unregulated research-chemical market: Belgian regulatory chemists identified epitalon in two illegal pharmaceutical preparations promoted for cancer, old age and retinitis pigmentosa [7]. A product compounded under the HHS policy must instead come from a registered manufacturer with a lot-level certificate of analysis and contain epitalon alone [1]. That improves what is in the vial. It does not supply the missing evidence of benefit.
Frequently asked questions
Is epitalon FDA-approved?
No. Epitalon has no FDA approval for any use. What exists is a draft HHS policy from October 28, 2026: HHS says it does not intend to bring enforcement action against 503A pharmacies and physicians that compound epitalon acetate as a subcutaneous or intramuscular shot, supplied in intermittent courses and meeting ten conditions. That is enforcement discretion while FDA works on the 503A bulks list, not approval.
What does epitalon do?
In a 2003 cell study, epitalon switched on telomerase and lengthened telomeres in cultured human fetal fibroblasts [2]. Other reported effects, including on melatonin synthesis, come from cell, animal and computer-modeling work [6]. In people, one small report from the developing group described better retinal function in retinitis pigmentosa [3]. No independent human trial shows that it slows aging.
Is epitalon safe?
Long-term safety in people is unknown. HHS notes that no side effects were reported in the few controlled human exposures on record [1], but those are small and mostly from the group that developed it. Quality is a separate problem: Belgian regulatory chemists found epitalon in illegal pharmaceutical preparations [7], and research-chemical vials have no verified identity or purity.
Does epitalon lengthen telomeres in people?
That has not been shown. The telomere finding is a 2003 study in cultured human fetal cells from the group that developed epitalon. No independent human study has shown that epitalon lengthens telomeres or slows aging.
What about the Russian studies showing lower mortality?
Those reports used epithalamin, a pineal-gland extract, not synthetic epitalon. One followed 266 older adults and reported 1.6 to 1.8 times lower mortality with the extract; another randomized 79 coronary patients and reported lower mortality over 15 years. Both come from the same research network and have not been replicated independently.
Under the HHS policy, what do 'intermittent courses' of epitalon mean?
The policy covers epitalon only when it is dispensed in intermittent courses rather than for continuous use. It does not define the length of a course or a dose. HHS cited the intermittent pattern of documented regimens as one reason for including it.
Does epitalon help with weight loss?
No study reports weight loss from epitalon in people, and its proposed mechanisms have nothing to do with appetite or fat loss. If weight is the goal, FDA-approved GLP-1 medications have large randomized trials behind them.
Is Epitalon banned in sports?
Epitalon is not named on WADA's 2026 Prohibited List. Its S0 class prohibits at all times any pharmacological substance not covered elsewhere on the List and not approved by any governmental health authority for human therapeutic use, so an athlete subject to anti-doping rules should check with their anti-doping organization before using it.
Sources
- [1] US Department of Health and Human Services. HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (Appendix A: list; Appendix B: identities, routes, and justifications). HHS (2026). Source
- [2] Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med (2003). PMID 12937682
- [3] Khavinson V, Razumovsky M, Trofimova S, Grigorian R, Razumovskaya A. Pineal-regulating tetrapeptide epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett (2002). PMID 12195242
- [4] Khavinson VKh, Morozov VG. Peptides of pineal gland and thymus prolong human life. Neuro Endocrinol Lett (2003). PMID 14523363
- [5] Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med (2011). PMID 22451889
- [6] Araj SK, Brzezik J, Mądra-Gackowska K, Szeleszczuk Ł. Overview of Epitalon-Highly Bioactive Pineal Tetrapeptide with Promising Properties. Int J Mol Sci (2025). PMID 40141333
- [7] Vanhee C, Moens G, Van Hoeck E, Deconinck E, De Beer JO. Identification of the small research tetra peptide Epitalon, assumed to be a potential treatment for cancer, old age and Retinitis Pigmentosa in two illegal pharmaceutical preparations. Drug Test Anal (2015). PMID 25535022
- [8] Willis J, Vu N. Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards. Int J Pharm Compd (2026). PMID 42752426
- [9] World Anti-Doping Agency. The 2026 Prohibited List (S0 Non-approved substances). WADA (2026). Source
Further reading
- Epitalon and longevity: the full evidence review Why the telomerase and lifespan claims stay unconfirmed.
- Epitalon providers Every clinic we confirmed sells single-ingredient epitalon, with the form each one sells. A listing does not confirm the pharmacy meets the policy's conditions.
- How the HHS 503A peptide policy works What the October 2026 policy allows, its ten conditions, and what it leaves out.
- News: HHS enforcement discretion for six compounded peptides Our report on the October 28, 2026 announcement.
- MOTS-c Another Appendix A peptide sold for aging and metabolism, with mouse data and no human trial.
- NAD+ The longevity compound with the most human data in our directory.
- Peptides A to Z Every peptide graded on the same evidence scale.
- All peptides we cover Evidence grades and regulatory status side by side.
Related peptides
Browse the full peptide directory, see what GLP-1s treat by condition, or compare the best GLP-1 providers.
Educational information only — not medical advice.